Details for Patent: 10,940,141

Which drugs does patent 10,940,141 protect, and when does it expire?

Patent 10,940,141 protects INGREZZA and is included in one NDA.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 10,940,141

Title:	Methods for the administration of certain VMAT2 inhibitors
Abstract:	Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
Inventor(s):	Loewen; Gordon Raphael (Solana Beach, CA), Luo; Sha Rosa (San Diego, CA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	16/989,206
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,940,141

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No						TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021		RX	Yes	No						TREATMENT OF TARDIVE DYSKINESIA
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes						TREATMENT OF TARDIVE DYSKINESIA

International Family Members for US Patent 10,940,141

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020336017
Brazil	112022002834
Canada	3149033
China	114679906
European Patent Office	4017494
Israel	290686
Jordan	P20220040